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Abstract ●Background:FK506 has
becn uscd for treatment of ccll―me―
diatcd immune disorders such as graft
raection in transplantation or Bch9ct
discase.To cvaluate the e∬ectivcness
of FK506 in anotllcr oculttr disease
model,we ittectcd FK506 in rats
with experilncntal allergic/immune―
mediated blcpharo cottunctivitis
(EAC)thc induction mechanism of
、vhich depend,on ccll―mcdiated im―
munity.●A/1ethods:Lewis rats were
immunizcd with Ovalbumin(OVA)in
emulsion of col■lplete Frcund's attu―
vant(CFA).We ittCCtCd 2(4=6),20
(72=6)or 200(77=5)μg of FK506 in―
tramuscularly daily fronl the day of
imlllunization(day O)tO day 6.Con―
trol rats were not treated with FK506
(れ=4).In addition,wc ittected 2oO μg
of FK506 from day 7 to day 13
(4=12)to compare the timing of
FK506 administration(day O to day
6,ん=12;control,Jz=12).Twenty―one
days after immunization,all rats were
challengcd with OVA by eyc drops,
and 24 h later they、vc c killed after
clinical evaluation and their eyes,
blood and draining lymph nodcs、vcrc
harvested for histology,antibody ti―
ters and proliferation assay or flow
cytometric analysis ln another set of
cxperilnents,rats that had received
OVA―primcd lylllph node cclls did
(77=9)Or did not(れ=9)rcceiVe addi―
ti nal FK506 by ittCCtiOn daily for 4
days Four days after transfer,these
rats we e challenged witl1 0VA and
valuated as inentioncd.To investi―
gate possible suppression of diseasc
by topical adlllinistration of FK506,
both actively immunized and pas―
sively immunized ra s rcccived OVA
together with O.3%(wcight/Volume)
of FK506(71=16)or vehiCle(71=10)
by cye d ops and 24 h after challcnge,
rats were evaluatcd as lnen―
tioned.●Rcsul s:Development of
discasc,induced by either active or
passivc immunization,was inhibited
in the group treated M/ith 200 μg of
FK506,regardless of tilning of ad―
nlinistration.Cellular proliferative
rcsponses to OVA were inhibitcd
only in tllis group.Flow cytometry
de o stratcd a decrease of about
209b in thc proportion of all cells
made up by CD4-positive T cclls.
T pica adnlinistration of FK506 in―
hibited tlle devclopmcnt of EAC,
tllough not signiicantly. ●Con lu―
sions:Systenlic treatinent with 200
μg of FK506 eithcrin the induction or
the effector phasc inhibits the devel―
opment of EAC in Lewis rats.Topi―
cal adlllinistration is not so effcctivc
as systenlic adlllinistration.
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introduction
Allergic cOttunctiVitis is a grOup of diseases charactcrized
by hyperscnsitivc immunc―mediatcd inllammation against
exogenous antigens in the cottunctiVa[6].Clinical and
experilllental reports have dcmonstratcd that lgE―me iat―
ed ilninediate responses arc dolninant lnechanisms for the
development of this discase [5, 15] Although humOral
immunity is thc mttor cffectOr mechanism for the devel―
opment of allcrgic cottunctivitis,cellular immunity is
also thought tO be invOlved in the devc10pment Of certain
kinds Of allcrgic cottunCtiVitis such as vernal keratocon―
juncti宙tis(VKC)[1,3]Rccently,we demonstrated the
cssential r01e of ccllular irlDInunity fOr thc induction of ex―
perimental allcrgic/immune mcdiated blepharocOttuncti_
宙tis(EAC)in Lewis rats[8].The histopath01ogical fca―
turcs of EAC are sirnilar to those of VKC In our systcm,
EAC was induced either by active immunization or adop―
tive transfer of allergen―priined lymph node cells.
FK506 is known to suppress cellular immunity by in―
hibiting production of cytokincs and IL-2 reccptor exprcs―
sion of T cclls,leading to rcduction in number and func―
tion of CD4-positive T cclls[2,18].FK506 excrts its ei
fects at 10-100 tillles lower concentrations than cyclo―
sporin A(CsA)[19]Therefore,it has been used both in
experilnental anil■als and in humans fOr treatlllent of
cell―mediated immune disorders such as graft racction
in organ transplantation[20,21].
Conccrning cye discases,Mochizuki et al cxtensively
studicd the effects of systelllic adnlinisttation of FK506 in
expcrilnental autoilnmune uveitis[7, 12]and in patients
with uveitis[17].In addition,they investigated thc effect
of topical application of FK506 or CsA on endotoxin―in―
duced uvcitis[9]Or cOrncal allograft transplantation[10]
and demonstratcd the cffectivcness in tcrms of supprcs―
sion of deve10pment Of disease.
For thc treatmcnt of allcrgic cottunCt市itis,anti―h sta―
nline drugs are the first chOice,and topical steroid therapy
is selccted for severc cases[H]Reccntly,however,im―
munosuppressive drugs targetcd to T cells,such as cyc10-
sporin A or FK506,were discovercd,and trials of topical
administratiOn demonstratcd that these drugs werc just as
cffectivc as cOrticosteroids[11]. In addition tO allergic
COttunctivitis,treatmcnt of FK506 cffcctively supprcssed
the development of allergic diseascs such as contact der―
matitis[13,14]These rcports prompted us to investigatc
the inhibitory effects of cither systemic or topical admin―
istration Of FK506 on EAC in Lewis rats,in which cenu―
lar immunity is dOnlinantly inv01ved.
Materials and methods
Rats
Six―to 8-week-01d inalc Lewis rats were purchased
cial sOurce(Scac Yoshitonll,Fukuoka,」apan)and
speciflc PathOgen―frcc animal facility at Kochi Ⅳledical S ool
All animal proccdures conformed tO institutional guidelines and
the、´RVO Rcsolution on Usc Ofノnヽilalals in Rescarch
Reagents
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Fig。l a Clinical grading of EAC(Dose rcsponse of FK506)Tested
groups of rats reccivcd 2 μg,20 μg,or 200 μg of FK506 daily from
day O to 6 by intramuscular illJection Control rats wcrc not treated
with FK506 Each dot indicates an individual rat Clinical grading
was scored following Materials and mcthods
10 μl of FK506 by eye drops(72=16)Cont1 01 rats wcre treated with
vchiclc by cyc drops(77=10)TWenty―four hours later,all rats were
clinically cvaluated and Hlled for histological study
Clinical grading and histological studics of collJunCtiVa
Thc clinical scoring system used was based on our prcvious rcport
[8]In briCf,each cyc was asscssCd fOr the flndings of lid swelling
and dischargc, and cach flnding was scored as one point Ocular
changes M′ere also examined hist010gically Aftcr clinical evalua―
tion,eyes,including the lids,wcrc flxcd in 10%buffered formalin
and cmbcddcd in paraffln Ten―nllcromet r sectlons were cut and
staincd with hematoxylin and eosin All the iniltrated cclls which
v′e could not categorize as macrophagcs or lymphocytes by this
staining wcrc countcd in thc palpcbral colllunCtiVa per fleld,using
]ξ:灘滞 電ソtl淵温駈鼈1¶ltli胤1導』」::稀謝:1
thc normal colllunCtiVa of the rat
Proliferative responses of draining lymph nOdc ccls
Lymph nodcs or spleens fronl tv′o or th ee rats 、v re combincd in
cach group and experiments、vere repeated as recorded Lymph nodc
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Fig。l b Histology ofthe con―
junctiva of rats with EAC cither
untrcatcd or trcatcd wlth FK506
スわοッ′i not tleated at all:bι′οll r
treated with 200 μg of FK506
from day O to day 6 Rats were
activcly immunizcd with OVA
and challenged with OVA by
eye drops as dcscribcd in Mate―
rials and methods Magniflca―
tion×320
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Anti-OVA antibody titers Of serulll fronl rats
BRL,Gaithersburg,ⅣId),and the Optical density(OD)for caCh Well
was read at 610 nm
Flow cytOmetry
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Statistical analysis
Statistical cOlllparisOn of the number of inflltrated cells bet、vccn t、vo
groups was pcrformcd using Student'st_tcst
Resuits
Systenlic FK506 treatFllent:dose rcsponsc
To test thc dosc requircd to inhibit the induction of EAC,
we inJected three different doses of FK506(2 μg,20 μg
and 200 μg)frOm day O to day 6 intramuscularly.As
shown in Fig. 1, Only daily adnlinistratiOn of 200 μg
FK506 was effcctive fOr suppression of EAC This result
、vas in accOrdance、vith the inding that lymph node cens
of rats treated with 200 μg of FK506 exhibited lo、ver pro―
liferative responses than thOse of other groups. Cellular
illlinunity against(Dヽらへin the grOups of rats trcated with
縄 .■,喘 習 需 壻淵 「 鵬 蹴 ξ『 Ⅷ ″ 器
lymph node cells rccOvercd from each rat amOng all the
groups(TablC l)Although there were no remarkable dii
麗 鶴 亀 ぶ 』=瑠 鍋 ;w躙 淵 棚 金tξT鮮
ed with 200 μg of FK506 exhibited dilllinishcd prolifera―
tivc responses against PPE》comparcd to those from Othcr
groups(TablC l)
Group l      GrOup 2      Group 3
Table l Effccts Of systemic
Fk506 trcatinent on cellular
inllnuno10gical paramcters
TreatmentaAverage cells
recoveredb
ProliferatiOn againstC
OVA(100 μg/ml) COn A(l μg/ml)PPD(l μg/ml)
Number
of tested
rats
None
2 μg
20 μg
200 μg
648×106
510×106
755×106
58.2×106
17380
22494
15695
1479
74314
105187
60006
56120
4673
6391
5406
852
?
?
?
?
:惚釜1:::Лl∫懲辮階よ鷺鵠よモ亀I湖『1=冒鴛牌留瀧∫鶴Ⅷ鵬ど。f msC ProlifcratiOn assay pelfOrmcd as dcscl・lbed in Matcrials and methOds,data presentcd as dclta cpm(cpm
in prcsencc of testcd antigen―cPm withOut a tigens)
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―
 PBS
o- 20 ug
- 2 ug―●- 200 ug
1        10100
OVA concentration(ug/ml)
―
Group 3
-Group l
―
 Group 2
01        1        10       100
0VA concentration(ug/mり
Table 2 Data expressed as proportion of total cells tested that、/ere
positive(%)
Trcatmcnt  CD3CD4 CD45RA  LFA lCD8
15
あ10
5
0
10
8
227     273
223     484
a200 μg of FK506 illlected intramuscularly flom day O to day 6
Systemic FK506 treatment on EAC:
comparison of tillling of adnlinistration
To evaluate the influcncc of the tilllling of FK506 adnlin―
istration of the inhibition of thc induction of EAC,we in―
jected 200 μg ofFK506 intramuscularly daily,cithcr from
day O to day 6 orfrom day 7 to day 13.No animals cxccpt
for onc ratin group l and one in group 2 showed any clin―
ical pathologic changcs.In contrast,allnost all of the con―
trol rats had dischargc and/or lid swelling(Fig.2)Conl―
pared to the control group(grOup 3),both pr01ifcrative re―
sponscs(Fig 3a,b)and lgG production speciic to OVA
(Fig.3c)were inhibitcd in group l and group 2.Illlrnune
responses against Oヽしへ wcrc profoundly suppressed in
group l compared to group 2(Fig.3b,c).
Flow―cytolllctric analysis of lymph node cells
of FK506-trcatcd rats
Lymph node cells from group l and g■oup 3 wcrc tcstcd
for their surface ma『kers by FACscan analysis.As shown
in Tablc 2,a20%decrease was detected in both CD3-or
CI)4-positivc cells in the FK506-treated group compared
to thc control group.In contrast,pcrcentages of cells pos―
itive for CD45RA,which is a B cell rnarkcr,rclatively in―
creascd. Taking the data of Table l into considcration,
FK506 inhibited thc incrcase of CD4-positive T cells in
vivo,while B cells werc not affccted.
Systelllic FK506 treatment inhibited EAC
by adoptivc transfer of(DVA―pilned lymph node cells
To investigate the effects of FK506 on thc cffcctor phase
of EAC,we illiected 200 μg of FK5 6 each day frOm thc
day of transfer to the day of(DVA challenge.Cellular in―
■ltration was significantly suppressed(P<0.001)by treat―
ment with 200 μg of FK506(Fig 4a).Pr01iferative re
morc indcpcndcnt experiments The combined mean cpnnttSE valucs
in the unstilnulated control culturcs wcrc:group l:2348±288:group
2:7019±312:group 3:2135±1 8 c Measurcmcnt of OVA―spcciflc
lgG by ELISA in scrum iom rats Scrum was collected atthe time
of death and assayed for ELISA Thc X―axis indicates dilution fac―
tors of serum,while the y―axis d picts absorbance at 610 nm Sim―
ilar rcsults wcrc obtained in t、vo m re depe dent experilncnts
None
FK506a
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X10    ×40   ×160   X640  ×2560 X10240
Di:ution Factor
●― Group3 0   -●― G「oup2 0   - Group●0
-日= Group3 1   -●― GrOup2 1   - GrOupl l
C     モ Group3 2 -G,oup2 2 -Group1 2
Fig.3 a Proliferative respons,s of draining lymph node cclls
against OVA(dosc rCSponsc of FK506)Draining lymph nodc cells
frolll two to three rats were combined and tested for proliferation as
detailed in NIaterials and methods The recorded data are means of
stimulation index(SI)Values Similar rcsults wcrc obtaincd in an―
other experilnent The combined mean cpm±SE values i the un―
stiinulated control cultures 、/erei nonei ll15±47: 2 μg of FK506:
2591±341 20 μg of FK506:  1233±107; 200 μg of FK506:
897±16 b Proliferative responses of draining lymph node ells
against OVA(timing of FK506 illJcctiOn)Draining lymph nodc
cclls frOlln t、vo to thrcc rats wcrc combincd an  tested for prolifera―
tion detailed in inaterials and inethod The recorded data are means
of stimulation index values Similar results werc obtained in threc
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indicatcs the numbcr of iniltrated cells/mm2 b lnflltrated cell num―
bcr in the cOllJunCtiVa Of recipients Of OVA―primed clls either un
treated or trcated with tOpical FK506 Thc inflltrated cells wcrc
countcd in the palpcbral colllunctiva pcr fleld and theらαr indicates
standard deviation. The X―axis indicates the number of infiltrated
cclls/mm2
sponsc of splcnocytes frolll recipients trcated with FK506
was also inhibited cOmpared to the control rats(Fig.5).
Topical FK506 treatinent by eye drops partially
suppressed the severity of EAC
Thc data presentcd above shOw that systelnic treatlllcnt
with FK506 was effectivc fOr suppression of EAC.We
tested the possibility of suppression of EAC by treatinent
、vith topical FK506 in the form eye drops.In this study,
we used both active immunizatiOn and passive immuniza―
tion by adOptive transfer of OVA―priined lymph nodc
?
?
?
?
?
?
?
〓
?
??
?
??
?
OVA concentration(ug/ml)
―o― FK506(‐)   ―ロー  FK506(+)
Fig.5 Proliferativc rcsponses Of splenocytcs from recipicnts of
OVA―primed cclls SplenOcytes fronl two rats werc combined and
tested for pr01iferation as detailed in Materials and methods Thc re―
cordcd data arc mcans of stimulation indcx values of twO rats from
each group Silnilar results were obtaincd in two morc independcnt
cxperilncnts The combincd mean cPm±SE valucs in tlle unstimulat―
ed control culturcs were: FK506-treated: 75±3; no c inent:
177±31
cells. Thc number of cells infiltrated, induced by cither
active immunization(data nOt shown)or paSSiVe immuni―
zation(Fig 4b),waS dilllinished,though not signiicantly
SO(P=0.06).
Discusslon
Thc data recorded herc demonstrated the inhibitory ef―
fccts of FK506 adlllinistration On the dcvelopment Of
EAC using both active and passive iinlllunization sys―
tems.Although thc nature of the targct antigens(autoan_
tigen versus exogenous antigen)diffCred bet、vecn EAU
and EAC in Lewis rats,the inducing mechanism of bOth
disea es,which s mediated by cellular immunity[8,
16],is thOught to be similar,because transfer of CD4-pos―
itivc T cell linc specific to(DVA 323-339 peptidc induced
EAC after challenge with OVA in the forlll of cye drops
(un ubliShcd results)As itteCtiOn of FK506 effect市cly
inhibited the development of EAU[12],we teSted the
possiblc cffects of FK506 on the supprcssion of EAC
Thc r qu rcd dOse for suppression of EAC by systenlic
trcatine t during arly induction phase、vas 200 μg(Fig.
la)the same dosc as previously reportcd in the system
of EAU in Lewis ra s[12]Dose depcndency was ob―
served in the supprcssion of disease as wcll as the inhibi―
tion ofimmune rcsponses(Figs.la,3a).As shown in Ta―
0     20    40    60    80    100   120
:nfi:trated ce‖numberin the coniunCtiVa
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ble l, 200 μg of FK506 suppressed the proliferative re―
sponses of lymph node cells against PPI) as 、vell a
OVA, v/hile it did not affect the proliferation of lymph
node cells to Con A Thcsc data suggcst that FK506 in―
duccd non―antigcn―spccinc immunOsuppression and that
this extensive ilnmunosuppression led to the inhibition
of EAC
To compare the effccts oftiining of FK506 adlninistra―
tion atthe same amount,wc ittCCtCd 200 μg of FK506 ei―
ther during early induction phasc(frOm day O to day 6)or
late induction phasc(frOm day 7 to day 13).At this dose,
thcrc was no rcmarkable diffcrence in inhibitory effects
on EAC bctwcen thc two phases(Fig 2)Although cellu―
lar proliferative responses were inhibited in both groups,
(Fig. 3a, b)antibOdy production was not supprcssed in
the group trcatcd during latc induction phase(Fig. 3b,
C).ThCSC data furthcr supported our previous report tllat
cellular inllnunity, rather than humoral immunity, is in―
volved in the development of EAC [8] In additiOn, the
data could be interpreted as indicating that oncc B cclls
were prilllcd、vith OヽたA,thcir function could not be dis―
turbcd by FK506,whilc function of T cells could be in―
hibited by FK506 even after being priined.
Although the number of CD4-positive T cells in thc
group treated with 200 μg of FK506 is lo、ver than in thc
con廿ol group,there werc dcinitcly still CD4-positive T
cells in the former group(Table 2).PrcViOus rcports deln―
onstratcd that thc frcquency of soluble antigen―specific
cclls in immunized animals was in general lo、ver thall
l%[4],and therelbre,a20%decrcasc in CD4-positivc
T cells in the FK506-trcated group may also dcpcnd on
a decrease in the cell population not spccinc to ovA.
Taking Tablc l into considcration, it could be regarded
that not only OVA―spccinc but also OVA―unrelated
CD4-positivc T cclls were disturbed by FK506 treatment.
Therefore,the suppressive effects on EAC of the systclnic
adlllinistration of FK506 could bc partially attributed to a
decreasc in Oヽちヘーunrclatcd CID4-positive lylllph node
cclls as wcll as OVA―specinc cells.
It is also of note that CD8-positive cells、vere not af―
fected by FK506, although we did not test the function
of these cells As FK506 specifically blocks thc signaling
pathway initiated by T ccH rcccptor[2,18,19],CD4-pos―
itivc macrophages should not be affected.Frolll these da―
ta, as previously reported [12], FK506 speciically sup―
pressed CD4-positive T c。1ls WithOut affccting other phe―
notypes of cells such as CD8-positivc T cclls and macro―
phages
Although thc data on FK506 treatlnent in actively im―
munizcd rats indicated efficient suppression of EAC by
FK506,it could be considered that tllis inhibition lnight
depend on the suppression of thc maturation of CD4-pos―
itivc T cells during the induction stage.To test the effec―
tivcncss of FK506 during the effector phase,we ittected
FK506 into rats that had rcccived OVA―prilncd lymph
node cclls.Evcn though wc did not clariサwhCthCr
FK506 inhibited the functions of donor cells, recipient
ce ls or both,FK506 treatinent during tlle effector phase
inhibitcd thc dcvclopmcnt of EAC(Fig 4a)as wCll as ccl―
lular prolifcrative rcsponses against OVA(Fig.5).Includ_
ing the data of actively immunized rats,we concludcd that
ystelnic adlllinistration of FK506 is effective for inhibi―
ti n of EAC in both the induction and the effector phases.
Because EAC is a T ell―mediat d disease[8](unpub―
lished results), and FK506 should be easily available to
thc colliunCt市ain thc form cyc drops,thcrc is a good pos―
sibili y that topical adnlinistration of FK506 111ight be ef
fe ve for inh bition of disease. Some inhibition, albeit
not stat stically significant, 、va observed for ieatinent
with topical FK506(Fig.4b)Although we used FK506
江onc particular concentration(03%weight per volume),
this conccntration was dclnonstratcd to bc cffcctivc for
suppression of endotoxin―induced uveitis[15] With re―
spect to cyclospor  A, aO.4% concenttation was effec―
tivc to suppress the devclopmcnt of mast cell―mediated
COttunct市itics[22].HowCVCr,thc induction mcchanism
of EAC is diffcrcnt, and thcrcforc this conccntration Of
topical FK506 may no  b  high enough to inhibit EAC.
Dose―dependen y of FK506 on inhibition(Fig.la,Ta―
ble l)indicat d that the amount adlllinistered in vivo is
i lpo tant for thc cffcctivcness of FK506 Thc route of ad―
lll isiation is also important,becausc topical application
by eye drops must affect iniltrated cells more directly.
Concerning the adoptive transfer systenl in this study,
the total amount of FK506 given by systenlic adIIlinistra―
ion was l mg,、vhile that by topical was approxilnately
4.2 μg.Thcrcforc,a possiblc cxplanation for diffcrcnccs
in cffcctivcncss of FK506 b twccn systcmic and topical
administration is hat systemic administration may lead
to a higher an  continuous FK506 concentration in blood
and also to a higher concentration of FK506 in the con―
junctiva.
Thc data prcscntcd hcrc dcmonstratc,for thc first timc,
the effcctive inhibition by FK506 of the development of
ex erillllental allergic conJunctiVitis induced by exoge―
nOuS antigCns.From thcsc data,FK506,cspccially by sys―
tcmic administr tion,may bc a candidatc for thc thcrapy
of cer ain types of cell―m diated cottunCti宙is in humans.
In addition,topical adlllinistration of FK506,in combina―
tion、vith other drugs such as topical steroids,Inay be ef―
fective in the tr atment of allergic cottunct市itis
Acknov71edgement Wc would likc to thank Ms Natsuko Naruoka
for her technical help in preparation of histological slides
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